Compare Stocks → Buy Friday. Sell Monday. (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EMBCNASDAQ:SIBNNASDAQ:SILKNASDAQ:TMCI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMBCEmbecta$13.79+34.3%$12.05$9.93▼$32.00$794.01M0.86426,226 shs2.16 million shsSIBNSI-BONE$15.49+3.3%$15.78$13.96▼$29.51$638.19M1.24432,610 shs220,105 shsSILKSilk Road Medical$20.39+6.0%$17.89$6.08▼$37.99$804.18M1.43779,198 shs345,451 shsTMCITreace Medical Concepts$4.36+4.6%$11.82$3.92▼$27.70$269.27M0.37666,326 shs2.99 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMBCEmbecta-2.65%+1.38%-15.40%-42.17%-64.90%SIBNSI-BONE-4.34%+3.38%-2.09%-28.94%-30.81%SILKSilk Road Medical-6.47%-4.61%+9.70%+15.63%-54.02%TMCITreace Medical Concepts-62.50%-61.60%-65.93%-72.38%-83.33%You missed the class - here’s your second chance (Ad)It’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore…Click here and I’ll give you the details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMBCEmbecta3.3454 of 5 stars1.84.03.30.02.23.31.9SIBNSI-BONE4.2818 of 5 stars4.51.00.03.32.42.50.6SILKSilk Road Medical2.9801 of 5 stars2.11.00.04.33.21.70.6TMCITreace Medical Concepts2.733 of 5 stars4.11.00.00.01.93.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMBCEmbecta1.50Reduce$16.0016.03% UpsideSIBNSI-BONE3.00Buy$27.2976.15% UpsideSILKSilk Road Medical2.18Hold$22.5510.57% UpsideTMCITreace Medical Concepts2.14Hold$13.57211.27% UpsideCurrent Analyst RatingsLatest SIBN, EMBC, TMCI, and SILK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $16.005/8/2024TMCITreace Medical ConceptsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$15.00 ➝ $5.505/8/2024TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$17.00 ➝ $7.005/8/2024TMCITreace Medical ConceptsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$15.00 ➝ $6.005/8/2024TMCITreace Medical ConceptsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.005/8/2024TMCITreace Medical ConceptsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/7/2024SIBNSI-BONEJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$32.005/7/2024SIBNSI-BONEMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $25.005/7/2024SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/1/2024SILKSilk Road MedicalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $21.005/1/2024SILKSilk Road MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$18.00 ➝ $20.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMBCEmbecta$1.12B0.71$5.01 per share2.75($14.34) per share-0.96SIBNSI-BONE$138.89M4.59N/AN/A$4.18 per share3.71SILKSilk Road Medical$177.13M4.54N/AN/A$3.88 per share5.26TMCITreace Medical Concepts$187.12M1.44N/AN/A$2.24 per share1.95Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMBCEmbecta$70.40M$0.9514.526.24N/A4.93%-18.66%12.38%5/9/2024 (Confirmed)SIBNSI-BONE-$43.34M-$1.14N/AN/AN/A-31.20%-28.22%-20.53%8/5/2024 (Estimated)SILKSilk Road Medical-$55.74M-$1.37N/AN/AN/A-29.02%-35.12%-20.45%8/6/2024 (Estimated)TMCITreace Medical Concepts-$49.53M-$0.81N/AN/AN/A-26.47%-33.96%-19.99%8/13/2024 (Estimated)Latest SIBN, EMBC, TMCI, and SILK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AEMBCEmbecta$0.43$0.67+$0.24N/A$264.70 million$287.20 million 5/7/2024Q1 2024TMCITreace Medical Concepts-$0.30-$0.30N/A-$0.30$49.07 million$51.11 million 4/30/2024Q1 2024SILKSilk Road Medical-$0.40-$0.36+$0.04-$0.36$44.67 million$48.50 million 2/28/2024Q4 2023SILKSilk Road Medical-$0.40-$0.33+$0.07-$0.33$42.23 million$47.27 million 2/27/2024Q4 2023TMCITreace Medical Concepts-$0.09-$0.10-$0.01-$0.10$60.56 million$62.20 million 2/26/2024Q4 2023SIBNSI-BONE-$0.29-$0.27+$0.02-$0.27$38.60 million$38.86 million2/9/202412/31/2023EMBCEmbecta$0.46$0.61+$0.15$0.85$264.92 million$277.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMBCEmbecta$0.604.35%N/A63.16%N/ASIBNSI-BONEN/AN/AN/AN/AN/ASILKSilk Road MedicalN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ALatest SIBN, EMBC, TMCI, and SILK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/9/2024EMBCEmbectaQuarterly$0.153.69%2/27/20242/28/20243/15/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMBCEmbectaN/A2.201.75SIBNSI-BONE0.219.018.15SILKSilk Road Medical0.507.956.97TMCITreace Medical Concepts0.384.403.76OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMBCEmbecta93.83%SIBNSI-BONE98.11%SILKSilk Road MedicalN/ATMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipEMBCEmbecta0.28%SIBNSI-BONE5.40%SILKSilk Road Medical6.70%TMCITreace Medical Concepts24.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMBCEmbecta2,20057.58 million57.42 millionOptionableSIBNSI-BONE34441.20 million38.98 millionOptionableSILKSilk Road Medical47439.44 million36.80 millionOptionableTMCITreace Medical Concepts51661.76 million46.67 millionOptionableSIBN, EMBC, TMCI, and SILK HeadlinesSourceHeadlineBTIG Downgrades Treace Medical Concepts (TMCI)msn.com - May 9 at 12:22 PMTimesSquare Capital Management LLC Raises Stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI)marketbeat.com - May 9 at 12:57 AMOrthopedic Devices Maker Treace Medical Concepts' Gloomy Forecast Cast Concerns Over Long-Term Viabilitymsn.com - May 8 at 9:20 PMTreace Medical crashes as guidance cut prompts J.P. Morgan downgrademsn.com - May 8 at 9:20 PMTreace Medical Concepts (NASDAQ:TMCI) Stock Rating Lowered by Morgan Stanleymarketbeat.com - May 8 at 10:13 AMUBS Group Lowers Treace Medical Concepts (NASDAQ:TMCI) Price Target to $16.00marketbeat.com - May 8 at 10:13 AMTreace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Meets Estimatesmarketbeat.com - May 8 at 8:41 AMWhy Is Treace Medical Concepts (TMCI) Stock Down 59% Today?investorplace.com - May 8 at 8:34 AMTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - May 8 at 8:25 AMTreace Medical Concepts Inc (TMCI) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...finance.yahoo.com - May 8 at 7:19 AMTreace Medical Concepts Inc (TMCI) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Widensfinance.yahoo.com - May 7 at 9:17 PMTreace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimateszacks.com - May 7 at 6:31 PMTreace Medical Concepts Reports First Quarter 2024 Financial Resultsfinance.yahoo.com - May 7 at 4:17 PMTreace Medical Concepts (TMCI) Scheduled to Post Earnings on Tuesdayamericanbankingnews.com - April 30 at 4:34 AMTreace Medical Concepts is Now Oversold (TMCI)nasdaq.com - April 27 at 9:20 AMTreace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tourglobenewswire.com - April 24 at 7:00 AMTreace to Present at Bank of America Health Care Conferencefinance.yahoo.com - April 17 at 9:36 AMTreace Announces First Annual National Bunion Dayglobenewswire.com - April 16 at 7:00 AM7 Stable Stocks for 50% Returns by Early 2025investorplace.com - April 15 at 9:45 AMTreace Medical Concepts (NASDAQ:TMCI) Shares Down 5.2% marketbeat.com - April 12 at 3:17 PMTreace to Report First Quarter 2024 Financial Resultsglobenewswire.com - April 9 at 7:00 AMVanguard Group Inc. Has $54.93 Million Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI)marketbeat.com - April 9 at 4:08 AMTreace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestoneglobenewswire.com - March 25 at 7:00 AMTreace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 2:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEmbectaNASDAQ:EMBCEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.SI-BONENASDAQ:SIBNSI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Silk Road MedicalNASDAQ:SILKSilk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.Treace Medical ConceptsNASDAQ:TMCITreace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.